281.89
Veeva Systems Inc stock is traded at $281.89, with a volume of 1.15M.
It is down -0.95% in the last 24 hours and up +16.11% over the past month.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
See More
Previous Close:
$284.58
Open:
$282.47
24h Volume:
1.15M
Relative Volume:
0.81
Market Cap:
$46.43B
Revenue:
$2.86B
Net Income/Loss:
$780.66M
P/E Ratio:
59.72
EPS:
4.72
Net Cash Flow:
$1.20B
1W Performance:
-0.79%
1M Performance:
+16.11%
6M Performance:
+24.50%
1Y Performance:
+56.82%
Veeva Systems Inc Stock (VEEV) Company Profile
Name
Veeva Systems Inc
Sector
Industry
Phone
925-452-6500
Address
4280 HACIENDA DRIVE, PLEASANTON, CA
Compare VEEV with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VEEV
Veeva Systems Inc
|
281.89 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
![]()
TEM
Tempus Ai Inc
|
70.11 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
DOCS
Doximity Inc
|
58.51 | 11.00B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
HQY
Healthequity Inc
|
100.01 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
38.33 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-29-25 | Reiterated | Needham | Buy |
Jan-23-25 | Downgrade | Goldman | Buy → Sell |
Dec-20-24 | Initiated | Stephens | Overweight |
Dec-04-24 | Initiated | Mizuho | Outperform |
Nov-19-24 | Initiated | Scotiabank | Sector Perform |
Oct-08-24 | Initiated | Exane BNP Paribas | Outperform |
Aug-27-24 | Reiterated | Citigroup | Buy |
Jul-09-24 | Initiated | BTIG Research | Buy |
Oct-25-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Oct-13-23 | Initiated | Jefferies | Buy |
Jun-28-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jun-01-23 | Upgrade | Guggenheim | Neutral → Buy |
Mar-17-23 | Downgrade | Truist | Buy → Hold |
Feb-23-23 | Downgrade | Guggenheim | Buy → Neutral |
Jan-04-23 | Upgrade | Barclays | Equal Weight → Overweight |
Dec-06-22 | Initiated | Cowen | Market Perform |
Dec-02-22 | Reiterated | Needham | Buy |
Oct-31-22 | Initiated | Wells Fargo | Equal Weight |
Oct-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
Jul-27-22 | Initiated | Oppenheimer | Outperform |
Jun-23-22 | Initiated | Goldman | Buy |
Jun-21-22 | Resumed | Guggenheim | Buy |
Mar-03-22 | Downgrade | BofA Securities | Buy → Neutral |
Jan-28-22 | Initiated | Truist | Buy |
Jan-07-22 | Downgrade | Stephens | Overweight → Equal-Weight |
Jan-06-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Dec-16-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-01-21 | Resumed | Stifel | Buy |
Sep-02-21 | Reiterated | BofA Securities | Buy |
Sep-02-21 | Reiterated | JMP Securities | Mkt Outperform |
Sep-02-21 | Reiterated | Needham | Buy |
Sep-02-21 | Reiterated | UBS | Neutral |
Jul-21-21 | Initiated | Cowen | Outperform |
Mar-31-21 | Upgrade | UBS | Sell → Neutral |
Jan-07-21 | Resumed | KeyBanc Capital Markets | Overweight |
Dec-09-20 | Downgrade | JP Morgan | Neutral → Underweight |
Oct-14-20 | Resumed | UBS | Sell |
Aug-28-20 | Reiterated | Needham | Buy |
Jul-23-20 | Initiated | FBN Securities | Outperform |
Jul-07-20 | Initiated | Stephens | Overweight |
Jun-08-20 | Initiated | Citigroup | Buy |
May-29-20 | Reiterated | Needham | Buy |
Apr-13-20 | Initiated | SVB Leerink | Mkt Perform |
Feb-19-20 | Initiated | Robert W. Baird | Outperform |
Feb-14-20 | Initiated | Piper Sandler | Overweight |
Jan-13-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-27-19 | Reiterated | Canaccord Genuity | Hold |
Sep-26-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
Aug-28-19 | Reiterated | Needham | Buy |
Jun-07-19 | Initiated | Goldman | Neutral |
May-30-19 | Reiterated | BofA/Merrill | Buy |
May-30-19 | Upgrade | Stephens | Equal-Weight → Overweight |
May-24-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-17-19 | Reiterated | Needham | Buy |
Feb-27-19 | Reiterated | Needham | Buy |
View All
Veeva Systems Inc Stock (VEEV) Latest News
Cook Medical: Empowering Change Champions for a Global RIM Rollout - Veeva
VEEV Stock May Gain on the Launch of China Campaign Manager for Pharma - Yahoo Finance
Veeva Systems and PulteGroup have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Bull of the Day: Veeva Systems (VEEV) - Zacks Investment Research
Veeva Systems’ SWOT analysis: cloud leader faces competition in life sciences stock - Investing.com Nigeria
Radiometer Scales Clinical Trials with Unified Clinical Platform - Veeva
Veeva Systems Inc. (VEEV) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Why Veeva Systems (VEEV) is a Top Momentum Stock for the Long-Term - Yahoo Finance
New Veeva China Campaign Manager Drives Precision Omnichannel Marketing for Life Sciences - Veeva
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility - The Motley Fool
Veeva Systems (NYSE:VEEV) Powers Medtech Trials with Expanded Clinical Platform Adoption - Yahoo Finance
DOCS Boosts Client Retention via Workflow Integration and AI Tools - TradingView
Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech - marketscreener.com
Medtech Industry Establishes Foundation for Clinical Trials with - GuruFocus
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech – Company Announcement - Financial Times
Should You Expect a Large Market Opportunity for Veeva Systems (VEEV)? - MSN
Veeva Systems Inc. (VEEV): A Bull Case Theory - MSN
New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years - Veeva
Veeva Systems Inc. (VEEV) Stock Analysis: Navigating a $46 Billion Market Cap with Strong Revenue Growth - DirectorsTalk Interviews
Veeva Systems director Timothy Cabral sells $841,734 in stock By Investing.com - Investing.com Nigeria
Jefferies Hikes Veeva Systems (VEEV) Price Target to $335, Maintains Buy Rating - MSN
The Rich Compensation for Being the C.E.O. - The New York Times
Veeva Systems Inc. (NYSE:VEEV) Short Interest Update - Defense World
Alcon: Achieving UDI Compliance with Veeva RIM - Veeva
Do Options Traders Know Something About Veeva Systems Stock We Don't? - Nasdaq
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know - MSN
Veeva Systems: AI And Vault CRM Are Key Long-Term Tailwinds (NYSE:VEEV) - Seeking Alpha
Astellas Chooses Veeva Vault CRM as Global Standard - Yahoo Finance
Transcript : Veeva Systems Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-04-2025 01 - marketscreener.com
Veeva Systems (NYSE:VEEV) Partners With Accumulus Synergy For Global Regulatory Connectivity - Yahoo
Veeva Systems stock soars to 52-week high of $286.99 By Investing.com - Investing.com Nigeria
Veeva Systems stock soars to 52-week high of $286.99 - Investing.com Australia
Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials - BioSpace
Veeva Systems Signs Oncology Trial Software Deal With Sarah Cannon Research Institute - marketscreener.com
VEEV Teams Up with SCRI to Enhance Oncology Clinical Trials | VEEV Stock News - GuruFocus
Astellas Chooses Veeva Vault CRM as Global Standard | VEEV Stock News - GuruFocus
Astellas selects Veeva Vault CRM for global operations By Investing.com - Investing.com Canada
SCRI adopts Veeva platform for streamlined clinical trials By Investing.com - Investing.com Canada
Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials | VEEV Stock News - GuruFocus
Accumulus Synergy and Veeva Systems Partner to Advance Regulatory Transformation and Connectivity - marketscreener.com
Astellas Chooses Veeva Vault CRM as Global Standard – Company Announcement - Financial Times
Veeva Sees Inflows after Earnings Beat - FXEmpire
Decoding Veeva Systems Inc (VEEV): A Strategic SWOT Insight - GuruFocus
Transcript : Veeva Systems Inc. Presents at Baird Global Consumer, Technology & Services Conference 2025, Jun-03-2025 10 - marketscreener.com
Understanding Veeva (VEEV) Reliance on International Revenue - Yahoo Finance
Veeva Systems (NYSE:VEEV) Price Target Raised to $295.00 at Mizuho - Defense World
Insider Sell: Thomas Schwenger Sells 1,150 Shares of Veeva Syste - GuruFocus
VEEVA SYSTEMS INC SEC 10-Q Report - TradingView
Insider Sell: Thomas Schwenger Sells 1,150 Shares of Veeva Systems Inc (VEEV) - GuruFocus
Veeva Systems Inc Stock (VEEV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):